Clinically Relevant Updates in Dermatopathology: Where are the Gaps? An Update on Melanocytic Lesions

Conclusions

• Melanocytomas represent a category of skin lesions which may exhibit overlapping features with melanoma, necessitating careful diagnosis.
• Updated molecular insights suggest that initial mutations such as BRAF, NRAS, or HRAS mutations may lead to distinct secondary mutations in melanocytomas.
• Deep penetrating melanocytomas often feature mutations in beta-catenin which may indicate a more benign behavior when diagnosed appropriately.
• BAP1-inactivated melanocytomas (BIMT) require vigilance for familial syndromes due to their association with increased cancer risk.
• There is a distinct potential for pediatric melanocytic lesions to present differently from adults, with fewer BAP1 mutations found in children.
• BAMS spitzoid lesions are characterized by BRAF mutations without canonical Spitz mutations, requiring differentiation from Spitzoid melanoma.
• The classification and management of melanocytic tumors continue to evolve with better molecular characterizations and updated diagnostic criteria.
• Despite the benign appearance of some melanocytomas, underestimation of their potential risk may lead to inadequate treatment approaches.
• Immunohistochemistry has proven valuable in distinguishing between benign and malignant melanocytic lesions, particularly with markers such as BRAF V600E and BAP1.